Work

Epidemiology, Pathophysiology, and Prognostic Implications of Cystic Fibrosis–Related Diabetes

Year: 2010
Type: review
Abstract: Cystic fibrosis-related diabetes (CFRD) is the most common comorbidity in subjects with cystic fibrosis (CF).A consensus conference on CFRD was cosponsored by the Cystic Fibrosis Foundation (CFF), the American Diabetes Association (ADA), and the Pediatric Endocrine Society (PES) in September 2009.The committee's evidencebased recommendations for clinical management of CFRD are published in this issue of Diabetes Care.This review article describes the epidemiology, pathogenesis, and prognostic implications of CFRD. EpidemiologyCFRD is part of a continuum of glucose tolerance abnormalities, ranging from normal glucose tolerance (NGT), to impaired glucose tolerance (IGT), to CFRD without fasting hyperglycemia (CFRD FHϪ), to CFRD with fasting hyperglycemia (CFRD FHϩ) (Fig. 1).Unlike patients with type 1 diabetes, those with CFRD do not develop complete absence of insulin secretion.At the other end of the spectrum, few CF patients have truly normal glucose metabolism.Approximately 20% of children who are categorized as having NGT based on their fasting and 2-h oral glucose tolerance test (OGTT) glucose levels have glucose elevation Ͼ200 mg/dl (11.1 mmol/l) mid-OGTT, which is termed indeterminate glycemia (INDET) (1).As in the general population where INDET is a risk factor for progression to diabetes (2), INDET in children with CF is associated with early development of CFRD (1).Home continuous glucose monitoring (CGM) has shown that intermittent, asymptomatic hyperglycemia is common even in CF patients whose OGTT is normal, but the prognostic significance of these early impairments in glucose metabolism is unknown (3,4).Impaired fasting glucose has also been described in CF (5,6).CFRD is present in about 20% of adolescents and 40 -50% of adults with CF (7) (Fig. 2).It is rare in childhood but has been described in children of all ages including infants (8 -11).Beginning in the teenage years, the incidence is ϳ3%, with some but not all centers reporting an overall female predominance (7,12).In younger individuals CFRD FHϪ predominates, but the prevalence of fasting hyperglycemia rises with age (7).Diabetes is associated with more severe CF gene mutations, increasing age, worse pulmonary function, undernutrition, liver dysfunction, pancreatic insufficiency, and corticosteroid use (12-15).Pathophysiology CFRD shares features of both type 1 and type 2 diabetes, but has enough pathophysiological and clinical differences to warrant separate diagnostic classification (Table 1).As in type 1 diabetes, individuals with CFRD are not obese, it often occurs in young people, insulin insufficiency is the primary defect, and metabolic syndrome features (hyperlipidemia, hypertension, visceral adiposity) are not usually present.Clinical management is similar to type 1 diabetes in the honeymoon phase.As in type 2 diabetes, this is not an autoimmune disease, insulin resistance is present (albeit usually mild), and ketosis is rare.Genetically, CFRD may be related to type 2 diabetes, as described below.Insulin insufficiency.Reduced ␤-cell mass leading to insulin insufficiency is the hallmark of CFRD.The CF gene defect leads to abnormal or absent CF transmembrane conductance regulator (CFTR), a chloride channel that also influences sodium and water transport.Thick, viscous secretions cause inflammation, obstruction, and destruction of small ducts in the lungs, pancreas, liver, and reproductive organs.Autopsy findings include fibrosis and atrophy of the pancreas with ϳ50% reduction of the total islet mass (16 -18).Multiple studies have shown impaired first-phase insulin secretion in response to glucose, arginine, or glucagon, even in subjects with .In response to oral glucose, the earliest defect is delayed insulin secretion, followed over time by a progressively diminished total insulin response (22)(23)(24)(25)(26)(27)(28)(29)(30)(31)(32).The ␤-cell destruction is not complete and residual endogenous insulin secretion is present, so these patients are not prone to ketosis.The lack of ketosis may also be related to low glucagon levels.While fasting glucagon levels are normal, CF patients are not able to appropriately increase glucagon secretion in response to arginine or hypoglycemia (21,24), consistent with reduced ␣-cell mass.Incretin levels (gastric
Language: English
Field: Medicine
Open Access status: hybrid
OpenAlex ID: W2167789521
FWCI: 2.295
Cites: 81
Cited by: 305
Related to: 9